Takeda Pharmaceutical Company Limited
4502.T
Below: live stock price for Takeda Pharmaceutical Company Limited (4502.T), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Takeda Pharmaceutical Company Limited (4502.T) is a Healthcare company based in Japan. Operating in Drug Manufacturers - Specialty & Generic, it employs about 47,029 people. Over the past year 4502.T traded between 4,141 and 6,712 JPY. Trailing P/E sits near 297.98 on a market cap of about 10.62T JPY. It currently yields 3.07% in dividends.
- Prev close
- $41.09
- Volume (24h)
- $320.2M
- Market cap
- $67.45B
- Currency
- USD (native JPY)
Score
44/ 100 · Weak
- Value63
- Quality45
- Momentum72
- Growth38
- Risk52
- Dividend19
- Liquidity16
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 42.6255 +0.94%
- +20 bars
- 43.1771 +2.24%
- +60 bars
- 43.3924 +2.75%
- +120 bars
- 43.4003 +2.77%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.52% per bar.
Interpretation
Composite signals look weak. Strength: momentum with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value63/100
Value looks solid — driven by P/E (297.98).
P/E:297.98P/B:1.43PEG:0.47 - Quality45/100
Quality looks mixed — driven by Gross margin (64.77%).
ROE:0.56%ROA:2.89%Profit margin:0.87%Gross margin:64.77% - Momentum72/100
Momentum looks solid — driven by 52w change (58.51%).
52w change:58.51% - Growth38/100
Growth looks weak — driven by Revenue growth (6.70%).
Revenue growth:6.70% - Risk52/100
Risk looks mixed — driven by Debt / equity (72.23).
Beta:0.1Debt / equity:72.23 - Dividend19/100
Dividend looks fragile — driven by Payout ratio (905.02%).
Dividend yield:3.07%Payout ratio:905.02% - Liquidity16/100
Liquidity looks fragile — driven by Current ratio (1.15).
Current ratio:1.15Quick ratio:0.51
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 242 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 23.1%
- Max drawdown
- -19.4%
- Below period high
- 0.0%
- Best day
- +4.99%
- Worst day
- -4.63%
- Up days
- 55%
- Current streak
- 2 up
- Typical day swing
- 1.7%
- Volume vs average
- +19%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 42.2301 high → 33.1758 low · 60 bars
- ResistanceFib +161.8% extensionnot reached56.8799 USD+34.69% from current
- ResistanceFib +100% extensionnot reached51.2844 USD+21.44% from current
- ResistanceFib +61.8% extensionnot reached47.8256 USD+13.25% from current
- ResistanceFib +27.2% extensionnot reached44.6928 USD+5.83% from current
- Current42.2301 USD
- SupportFib 23.6% retracementNearesttested 4×40.0933 USD-5.06% from current
- SupportFib 38.2% retracementtested 1×38.7713 USD-8.19% from current
- SupportFib 50% midpointtested 5×37.7029 USD-10.72% from current
- SupportFib 61.8% retracementtested 12×36.6345 USD-13.25% from current
- SupportFib 78.6% retracementtested 6×35.1134 USD-16.85% from current
- SupportFib −27.2% extensionnot reached30.713 USD-27.27% from current
- SupportFib −61.8% extensionnot reached27.5802 USD-34.69% from current
- SupportFib −100% extensionnot reached24.1215 USD-42.88% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- ¥6,712
- 52w low
- ¥4,141
- 52w change
- 58.51%
- Day high
- ¥6,712
- Day low
- ¥6,371
- P/E (TTM)
- 297.98
- Forward P/E
- 47.38
- PEG
- 0.47
- Price / Book
- 1.43
- Beta (5Y)
- 0.1
- Enterprise value
- 15.55T
- EV / Revenue
- 3.31
- EV / EBITDA
- 12.18
- EPS (TTM)
- ¥22.32
- Forward EPS
- ¥140.39
- Dividend yield
- 3.07%
- Dividend rate
- ¥204
- Payout ratio
- 905.02%
- Revenue (TTM)
- 4.69T
- EBITDA
- 1.28T
- Free cash flow
- 663.85B
- Total cash
- 418.53B
- Total debt
- 5.36T
- Debt / Equity
- 72.23
- Current ratio
- 1.15
- Quick ratio
- 0.51
- Profit margin
- 0.87%
- Gross margin
- 64.77%
- Return on assets
- 2.89%
- Return on equity
- 0.56%
- Shares outstanding
- 1.6B
- Float
- 1.59B
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.1
- very stable
- 52-week change
- 58.51%
- Debt / Equity
- 72.23
- very high leverage
- Current ratio
- 1.15
- Quick ratio
- 0.51
- ROE
- 0.56%
- ROA
- 2.89%
- PEG ratio
- 0.47
- EV / Revenue
- 3.31
- EV / EBITDA
- 12.18
- Revenue growth
- 6.70%
- EBITDA
- 1.28T
- Free cash flow
- 663.85B
- Total cash
- 418.53B
- Total debt
- 5.36T
- Insider holdings
- 0.10%
- Institutional
- 50.18%
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.